72 related articles for article (PubMed ID: 23720363)
1. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
[TBL] [Abstract][Full Text] [Related]
2. Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes.
Wang J; Ai X; Qin T; Xu Z; Zhang Y; Liu J; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Cai W; Ru K; Jia Y; Huang G; Xiao Z
Oncotarget; 2017 Jan; 8(1):1603-1612. PubMed ID: 27906673
[TBL] [Abstract][Full Text] [Related]
3. Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience.
Al Zaabi EA; Fernandez LA; Sadek IA; Riddell DC; Greer WL
J Mol Diagn; 2010 Mar; 12(2):197-203. PubMed ID: 20093390
[TBL] [Abstract][Full Text] [Related]
4. Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients.
Ma J; Ai X; Wang J; Xing L; Tian C; Yang H; Yu Y; Zhao H; Wang X; Zhao Z; Wang Y; Cao Z
Ann Hematol; 2021 Sep; 100(9):2207-2214. PubMed ID: 33990890
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal defects in multiple myeloma.
Clarke SE; Fuller KA; Erber WN
Blood Rev; 2024 Mar; 64():101168. PubMed ID: 38212176
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Daudignon A; Cuccuini W; Bracquemart C; Godon C; Quilichini B; Penther D
Curr Res Transl Med; 2023; 71(4):103427. PubMed ID: 38035476
[TBL] [Abstract][Full Text] [Related]
7. Interpretation of cytogenetic results in multiple myeloma for clinical practice.
Rajan AM; Rajkumar SV
Blood Cancer J; 2015 Oct; 5(10):e365. PubMed ID: 26517360
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
Yadav U; Kumar SK; Baughn LB; Dispenzieri A; Greipp P; Ketterling R; Jevremovic D; Buadi FK; Dingli D; Lacy MQ; Fonseca R; Bergsagel PL; Ailawadhi S; Roy V; Parrondo R; Sher T; Hayman SR; Kapoor P; Leung N; Cook J; Binder M; Muchtar E; Warsame R; Kourelis TV; Go RS; Lin Y; Seth A; Lester SC; Breen WG; Kyle RA; Gertz MA; Rajkumar SV; Gonsalves WI
Blood; 2023 Nov; 142(22):1871-1878. PubMed ID: 37494698
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.
Cui J; Liu Y; Lv R; Yan W; Xu J; Li L; Du C; Yu T; Zhang S; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
Leukemia; 2024 Jun; 38(6):1299-1306. PubMed ID: 38609496
[TBL] [Abstract][Full Text] [Related]
10. ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous.
Moelans CB; Holst F; Hellwinkel O; Simon R; van Diest PJ
PLoS One; 2013; 8(12):e84189. PubMed ID: 24367641
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
Zhou P; Li W; Zuo S; Ma R; Yuan X; Zhu Z
Leuk Lymphoma; 2023; 64(8):1373-1388. PubMed ID: 37300424
[TBL] [Abstract][Full Text] [Related]
12. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
Croft J; Ellis S; Sherborne AL; Sharp K; Price A; Jenner MW; Drayson MT; Owen RG; Chown S; Lindsay J; Karunanithi K; Hunter H; Gregory WM; Davies FE; Morgan GJ; Cook G; Atanesyan L; Savola S; Cairns DA; Jackson G; Houlston RS; Kaiser MF
Leukemia; 2021 Jul; 35(7):2043-2053. PubMed ID: 33262523
[TBL] [Abstract][Full Text] [Related]
13. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma.
Caro J; Cairns D; Menzies T; Boyle E; Pawlyn C; Cook G; Kaiser M; Walker BA; Owen R; Jackson GH; Morgan GJ; Heaney J; Drayson MT; Davies FE
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e279-e284. PubMed ID: 34876373
[TBL] [Abstract][Full Text] [Related]
14. Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma.
Giguère A; Raymond-Bouchard I; Collin V; Claveau JS; Hébert J; LeBlanc R
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835381
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
Weinhold N; Salwender HJ; Cairns DA; Raab MS; Waldron G; Blau IW; Bertsch U; Hielscher T; Morgan GJ; Jauch A; Davies FE; Hänel M; Cook G; Scheid C; Houlston R; Goldschmidt H; Jackson G; Kaiser MF
Haematologica; 2021 Oct; 106(10):2754-2758. PubMed ID: 34092058
[No Abstract] [Full Text] [Related]
16. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.
Greenberg AJ; Rajkumar SV; Therneau TM; Singh PP; Dispenzieri A; Kumar SK
Leukemia; 2014 Feb; 28(2):398-403. PubMed ID: 24005246
[TBL] [Abstract][Full Text] [Related]
17. The genetic landscape of 5T models for multiple myeloma.
Maes K; Boeckx B; Vlummens P; De Veirman K; Menu E; Vanderkerken K; Lambrechts D; De Bruyne E
Sci Rep; 2018 Oct; 8(1):15030. PubMed ID: 30301958
[TBL] [Abstract][Full Text] [Related]
18. PRUNE1 (located on chromosome 1q21.3) promotes multiple myeloma with 1q21 Gain by enhancing the links between purine and mitochondrion.
Xu J; Wang Y; Li P; Chen C; Jiang Z; Wang X; Liu P
Br J Haematol; 2023 Nov; 203(4):599-613. PubMed ID: 37666675
[TBL] [Abstract][Full Text] [Related]
19. Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma.
Mansilla C; Soria E; Vallejo M; Valiente A; Perez-Juana A; Zabalza A; Hurtado G; Sala F; Ramírez N
Transl Oncol; 2018 Jun; 11(3):647-652. PubMed ID: 29604510
[TBL] [Abstract][Full Text] [Related]
20. Del(1p32): prime time in (ultra) high-risk myeloma.
Khot A
Blood; 2023 Mar; 141(11):1241-1243. PubMed ID: 36929439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
